Differentiated Thyroid Cancer Is Associated With Sex-specific Immune Response. [PDF]
Shobab L +14 more
europepmc +1 more source
Erratum: Predicting prognosis in lung adenocarcinoma by predicting TIGIT expression: a pathomics model. [PDF]
Editorial Office.
europepmc +1 more source
Beyond monotherapy: multimodal strategies integrating immune checkpoint inhibitors in lymphoma management. [PDF]
Li Y +6 more
europepmc +1 more source
Multidimensional plasticity of natural killer cells in tumours. [PDF]
Yang X, Song Z, Chen L, Jia Q, Li M.
europepmc +1 more source
Iron Deficiency Drives Th2-Mediated Immunity in Pediatric Atopic Dermatitis Through DNA Hypermethylation and TIGIT Suppression in IL-10-Producing Breg Cells. [PDF]
Gao X +10 more
europepmc +1 more source
Immunotherapy in clear cell renal cell carcinoma: current Status, novel Strategies, and future perspectives. [PDF]
Chen X +5 more
europepmc +1 more source
Related searches:
TIGIT-Fc Promotes Antitumor Immunity
Cancer Immunology Research, 2021Abstract T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is a checkpoint receptor that mediates both T-cell and natural killer (NK)–cell exhaustion in tumors. An Fc-TIGIT fusion protein was shown to induce an immune-tolerance effect in a previous report, but the relevance of the TIGIT ...
Xian, Shen +7 more
openaire +2 more sources
TIGIT limits immune pathology during viral infections [PDF]
AbstractCo-inhibitory pathways have a fundamental function in regulating T cell responses and control the balance between promoting efficient effector functions and restricting immune pathology. The TIGIT pathway has been implicated in promoting T cell dysfunction in chronic viral infection.
Michelle Schorer +2 more
exaly +7 more sources
Abstract Background: T-cell immunoreceptor with immunoglobulin and tyrosine based inhibitory motif domain (TIGIT) is a co-inhibitory immune checkpoint receptor expressed on several types of immune cells, which can suppress T-cell activation, promote T-cell exhaustion, and suppress natural killer cell mediated cytotoxicity.
Dmitry Shchelokov +7 more
openaire +1 more source
Tiragolumab Results Cast Shadow on TIGIT Pipeline
Cancer Discovery, 2022Abstract Genentech's TIGIT-targeted antibody tiragolumab missed its endpoints in two late-stage lung cancer trials, raising doubts about one of the most widely studied next-generation checkpoint targets in immuno-oncology. But numerical signs of benefit among certain patients with metastatic non–small cell lung cancer suggest that TIGIT ...
openaire +2 more sources

